{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:22:57Z","timestamp":1774578177944,"version":"3.50.1"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010476","name":"Tata Memorial Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Transplant related toxicity is a major therapeutic challenge. We have previously reported that the toxicity of chemotherapy is largely not directly because of the drugs themselves; rather it is mainly due to DNA damage, apoptosis and hyper-inflammation triggered by cell-free chromatin particles that are released because of drug-induced host cell death. Cell-free chromatin particles can be inactivated by free-radicals which are generated when the nutraceuticals resveratrol and copper are administered orally. We investigated if a combination of resveratrol and copper would reduce transplant related toxicities in an exploratory, prospective dose-escalation study.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Patients and methods<\/jats:title>\n<jats:p>Twenty-five patients with multiple myeloma were enrolled between March 2017 to August 2019. Patients were divided into 3 groups: control (Group 1, N = 5) received vehicle alone; group 2 (N = 15) received resveratrol-copper at dose level I (resveratrol = 5.6 mg and copper = 560 ng); group 3 (N = 5) received resveratrol-copper at dose level II (resveratrol = 50 mg and copper = 5 \u03bcg). The dose was given twice daily with the first dose administered 48 hours before administering melphalan and continued until day +21 post-transplant. Common Terminology Criteria for Adverse Events version 4.02 was used to assess toxicities which included oral mucositis, nausea, vomiting and diarrhea. Measurement of inflammatory cytokines was done by ELISA.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>All patients (100%) in the control group developed grade 3\/4 oral mucositis compared to 8\/20 (40%) in both resveratrol-copper group 2 plus group 3 combined (P = 0.039). Reduction in inflammatory cytokines: salivary TNF - \u03b1 (p = 0.012) and IL\u20141\u03b2 (p = 0.009) in dose level I but not in dose level II was observed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>A combination of resveratrol-copper reduced transplant related toxicities in patients with multiple myeloma receiving high dose melphalan. We conclude that relatively inexpensive nutraceuticals may be useful as adjuncts to chemotherapy to reduce its toxicity.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Registration<\/jats:title>\n<jats:p>The trial was registered under Clinical Trial Registry of India (no.<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=17626&amp;EncHid=&amp;userName=CTRI\/2018\/02\/01190\" xlink:type=\"simple\">CTRI\/2018\/02\/011905<\/jats:ext-link>).<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0262212","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T18:32:51Z","timestamp":1643999571000},"page":"e0262212","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["A novel pro-oxidant combination of resveratrol and copper reduces transplant related toxicities in patients receiving high dose melphalan for multiple myeloma (RESCU 001)"],"prefix":"10.1371","volume":"17","author":[{"given":"Anshul","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakanksha","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen Kumar","family":"Khare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murarilal","family":"Gurjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Punatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anant","family":"Gokarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avinash","family":"Bonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingaraj","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadhana","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Gota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navin","family":"Khattry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5768-3821","authenticated-orcid":true,"given":"Indraneel","family":"Mittra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"pone.0262212.ref001","first-page":"2714","volume-title":"Cancer; Principles and Practice of Oncology","author":"AM Berger","year":"1997","edition":"5"},{"key":"pone.0262212.ref002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0964-1955(94)90059-0","article-title":"Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care","volume":"30B","author":"B Borowski","year":"1994","journal-title":"Eur J Cancer B Oral Oncol"},{"issue":"4","key":"pone.0262212.ref003","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0030-4220(91)90552-N","article-title":"Oral mucositis after bone marrow transplantation. A marker of treatment toxicity and predictor of hepatic veno-occlusive disease","volume":"72","author":"J R Wingard","year":"1991","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"12","key":"pone.0262212.ref004","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/sj.bmt.1702447","article-title":"Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for hematological malignancy: an overview","volume":"25","author":"NMA Blijlevens","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"pone.0262212.ref005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12038-015-9508-6","article-title":"Circulating nucleic acids damage DNA of healthy cells by integrating into their genomes","volume":"40","author":"I Mittra","year":"2015","journal-title":"J. Biosci"},{"key":"pone.0262212.ref006","doi-asserted-by":"crossref","first-page":"17015","DOI":"10.1038\/cddiscovery.2017.15","article-title":"Cell-free chromatin from dying cancer cells integrate into genomes of healthy cells to induce DNA damage and inflammation","volume":"3","author":"I Mittra","year":"2017","journal-title":"Cell Death Discov"},{"issue":"6","key":"pone.0262212.ref007","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/genes10060407","article-title":"Illegitimate and repeated genomic integration of cell-free chromatin in the aetiology of somatic mosaicism, ageing, chronic diseases and cancer","volume":"10","author":"G V Raghuram","year":"2019","journal-title":"Genes"},{"issue":"2","key":"pone.0262212.ref008","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/genes12020163","article-title":"A New Perspective on the Origin of DNA Double-Strand Breaks and Its Implications for Ageing","volume":"12","author":"B K Tripathy","year":"2021","journal-title":"Genes"},{"issue":"9","key":"pone.0262212.ref009","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdx318","article-title":"Prevention of chemotherapy toxicity by agents that neutralize or degrade cell-free chromatin","volume":"28","author":"I Mittra","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"pone.0262212.ref010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nut.2015.08.017","article-title":"Beneficial action of resveratrol: How and why?","volume":"32","author":"GT Diaz-Gerevini","year":"2016","journal-title":"Nutrition"},{"issue":"22","key":"pone.0262212.ref011","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1016\/S0960-894X(98)00585-X","article-title":"Resveratrol as a new type of DNA-cleaving agent","volume":"8","author":"K Fukuhara","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"pone.0262212.ref012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jtemb.2016.02.006","article-title":"Dietary copper and human health: Current evidence and unresolved issues","volume":"35","author":"M Bost","year":"2016","journal-title":"J Trace Elem Med Biol"},{"key":"pone.0262212.ref013","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.12688\/f1000research.7202.1","article-title":"A paradoxical relationship between Resveratrol and copper (II) with respect to degradation of DNA and RNA","volume":"4","author":"S Subramaniam","year":"2015","journal-title":"F1000Res"},{"issue":"3","key":"pone.0262212.ref014","doi-asserted-by":"crossref","first-page":"e0229017","DOI":"10.1371\/journal.pone.0229017","article-title":"Cell-free chromatin particles released from dying host cells are global instigators of endotoxin sepsis in mice","volume":"15","author":"I Mittra","year":"2020","journal-title":"PLoS ONE"},{"issue":"12","key":"pone.0262212.ref015","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41419-018-1181-x","article-title":"Prevention of radiation-induced bystander effects by agents that inactivate cell-free chromatin released from irradiated dying cells","volume":"9","author":"S Kirolikar","year":"2018","journal-title":"Cell Death Dis"},{"key":"pone.0262212.ref016","unstructured":"TRANSMAXTM | Biotivia [Internet]. [cited 2020 Sep 19]. Available from: https:\/\/www.biotivia.com\/product\/transmax\/"},{"key":"pone.0262212.ref017","unstructured":"Chelated Copper | 5 mg | Heart & Nerve Health [Internet]. [cited 2020 Sep 19]. Available from: https:\/\/carlsonlabs.com\/chelated-copper\/"},{"issue":"3","key":"pone.0262212.ref018","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"S Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"issue":"1","key":"pone.0262212.ref019","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01386402","article-title":"Characterization of the speed of convergence of the trapezoidal rule","volume":"57","author":"QI Rahman","year":"1990","journal-title":"Numer Math"},{"key":"pone.0262212.ref020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41232-019-0101-5","article-title":"The role of interleukin-1 in general pathology","volume":"39","author":"N Kaneko","year":"2019","journal-title":"Inflamm Regen"},{"issue":"6","key":"pone.0262212.ref021","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1200\/JOP.0868502","article-title":"2008 clinical practice guideline update summary: use of chemotherapy and radiation therapy protectants","volume":"4","author":"American society of clinical oncology","year":"2008","journal-title":"J Oncol Pract"},{"key":"pone.0262212.ref022","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3389\/fphar.2018.01374","article-title":"Preventive effect of curcumin against chemotherapy-induced side-effects","volume":"9","author":"Z Liu","year":"2018","journal-title":"Front. Pharmacol"},{"issue":"6","key":"pone.0262212.ref023","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.bbmt.2014.02.025","article-title":"Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation","volume":"20","author":"AK Nooka","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"pone.0262212.ref024","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2008.03.057","article-title":"Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives","volume":"269","author":"JK Kundu","year":"2008","journal-title":"Cancer Lett"},{"key":"pone.0262212.ref025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2010.05870.x","article-title":"Resveratrol and cellular mechanisms of cancer prevention","volume":"1215","author":"Y Shukla","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"pone.0262212.ref026","doi-asserted-by":"crossref","first-page":"R209","DOI":"10.1530\/ERC-13-0171","article-title":"Resveratrol and cancer: focus on in vivo evidence","volume":"21","author":"LG Carter","year":"2014","journal-title":"Endocr Relat Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T18:33:14Z","timestamp":1643999594000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262212"}},"subtitle":[],"editor":[{"given":"John W.","family":"Glod","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0262212","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]}}}